Diabetes

Among adults with type 1 diabetes, researchers explore how additional autoimmune diseases impacted patients’ physical and mental health burdens.

Among individuals with both diabetes and HIV, researchers determine patients’ adherence to comprehensive diabetes care interventions.

Medtronic’s diabetes management technology reached 2 milestones upon FDA approval, allowing integration of continuous glucose monitoring for patients with type 1 and type 2 diabetes.

Orforglipron shows results in weight loss and diabetes management, offering a new oral treatment option for patients.

With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.

Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.

However, caution with empagliflozin use should be applied for patients previously taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Certified diabetes care and education specialists and clinical pharmacists are essential members of diabetes care teams.

Investigators emphasize the importance of proper education regarding diabetes and continuous glucose monitors.

In association with patients’ race, ethnicity, and social determinants of health, researchers explored the off-label prescribing of GLP-1s approved for type 2 diabetes.

Sustainable CGM counseling combines pharmacist expertise, technician support, multimodal education, and policy advocacy to improve patient outcomes in diabetes care.

Targeted education and hands-on experience are helping pharmacists gain the confidence needed to guide patients in continuous glucose monitoring.

Recent studies reveal that while diabetes technology use rises, glycemic control in type 1 diabetes patients remains low, highlighting significant disparities.

In the context of the COVID-19 pandemic, researchers investigated how insulin use and glycemic control were associated among patients with type 2 diabetes.

Pharmacists play a key role in guiding patients on GLP-1 and dual agonist therapies, supporting safe use, managing adverse effects, and promoting long-term treatment success.

As continuous glucose monitoring becomes more common, pharmacists are essential in patient education but face barriers of time, training, and reimbursement.

Leveraging staff support, multimodal education, and policy change can make CGM counseling more sustainable in community pharmacies.

Among patients with type 2 diabetes, researchers explored how tirzepatide or semaglutide use was associated with first-time reports of optic nerve or visual pathway disorders.

Pharmacists can build confidence with CGMs through hands-on experience, continuing education, and strong support from employers, peers, and manufacturers.

Investigators found that health care costs rose despite the benefits seen with starting semaglutide for patients with and without diabetes.

Pharmacists are key to CGM education, but time, training, and reimbursement remain major barriers.

Compounding pharmacies help meet patient needs by formulating alternative versions in the face of drug shortages but are no longer allowed to compound them.

Investigators find modest improvements in body weight at week 26 for CT-868 compared with the placebo.

New research shows metformin's inconsistent neuroprotective effects against Alzheimer disease, challenging its role in diabetes management for cognitive health.

Patients with type 2 diabetes and moderate cardiovascular risk had a higher rate of major heart-related events when treated with sulfonylureas.